Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0239946 (
liver fibrosis
)
8,268
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatoma-derived growth factor
(
HDGF
) overexpression is involved in
liver fibrosis
and carcinogenesis. However, the receptor(s) and signaling for
HDGF
remain unclear. By using affinity chromatography and proteomic techniques, nucleolin (NCL) was identified and validated as a
HDGF
-interacting membrane protein in hepatoma cells. Exogenous
HDGF
elicited the membrane NCL accumulation within 0.5 hour by protein stabilization and transcriptional NCL upregulation within 24 hours. Blockade of surface NCL by antibodies neutralization potently suppressed
HDGF
uptake and
HDGF
-stimulated phosphatidylinositol 3-kinase (PI3K)/Akt signaling in hepatoma cells. By using rescectd hepatocellular carcinoma (HCC) tissues, immunohistochemical analysis revealed NCL overexpression was correlated with tumour grades, vascular invasion, serum alpha-fetoprotein levels and the poor survival in HCC patients. Multivariate analysis showed NCL was an independent prognostic factor for survival outcome of HCC patients after surgery. To delineate the role of NCL in liver carcinogenesis, ectopic NCL overexpression promoted the oncogenic behaviours and induced PI3K/Akt activation in hepatoma cells. Conversely, NCL knockdown by RNA interference attenuated the oncogenic behaviours and PI3K/Akt signaling, which could be partially rescued by exogenous
HDGF
supply. In summary, this study provides the first evidence that surface NCL transmits the oncogenic signaling of
HDGF
and facilitates a novel diagnostic and therapeutic target for HCC.
...
PMID:Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis. 2593 38